180 related articles for article (PubMed ID: 35031791)
41. Unethical studies of ivermectin for covid-19.
Meyerowitz-Katz G; Wieten S; Medina Arellano MJ; Yamey G
BMJ; 2022 Apr; 377():o917. PubMed ID: 35422425
[No Abstract] [Full Text] [Related]
42. COVID-19 in Still's disease.
de Carvalho JF
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12627-12629. PubMed ID: 33378008
[No Abstract] [Full Text] [Related]
43. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
Schluger NW
Ann Intern Med; 2020 Oct; 173(8):662-663. PubMed ID: 32673059
[TBL] [Abstract][Full Text] [Related]
44. Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Lee KH; Kim JS; Hong SH; Seong D; Choi YR; Ahn YT; Kim KS; Kim SE; Lee S; Sim W; Kim D; Jun B; Yang JW; Yon DK; Lee SW; Kim MS; Dragioti E; Li H; Jacob L; Koyanagi A; Abou Ghayda R; Shin JI; Smith L
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):13089-13097. PubMed ID: 33378062
[TBL] [Abstract][Full Text] [Related]
45. Curating the Evidence About COVID-19 for Frontline Public Health and Clinical Care: The Novel Coronavirus Research Compendium.
Redd AD; Peetluk LS; Jarrett BA; Hanrahan C; Schwartz S; Rao A; Jaffe AE; Peer AD; Jones CB; Lutz CS; McKee CD; Patel EU; Rosen JG; Garrison Desany H; McKay HS; Muschelli J; Andersen KM; Link MA; Wada N; Baral P; Young R; Boon D; Grabowski MK; Gurley ES;
Public Health Rep; 2022; 137(2):197-202. PubMed ID: 34969294
[TBL] [Abstract][Full Text] [Related]
46. The perils of preprints.
van Schalkwyk MCI; Hird TR; Maani N; Petticrew M; Gilmore AB
BMJ; 2020 Aug; 370():m3111. PubMed ID: 32816814
[No Abstract] [Full Text] [Related]
47. Disgraced COVID-19 studies are still routinely cited.
Piller C
Science; 2021 Jan; 371(6527):331-332. PubMed ID: 33479130
[No Abstract] [Full Text] [Related]
48. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
De Schryver N; Serck N; Vinetti M; Gérard L
Int J Antimicrob Agents; 2021 Jan; 57(1):106254. PubMed ID: 33259917
[No Abstract] [Full Text] [Related]
49. Examining linguistic shifts between preprints and publications.
Nicholson DN; Rubinetti V; Hu D; Thielk M; Hunter LE; Greene CS
PLoS Biol; 2022 Feb; 20(2):e3001470. PubMed ID: 35104289
[TBL] [Abstract][Full Text] [Related]
50. Repurposing antimalarials and other drugs for COVID-19.
Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
[No Abstract] [Full Text] [Related]
51. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA; Wagstaff KM
Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233
[TBL] [Abstract][Full Text] [Related]
52. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19.
Lee Z; Rayner CR; Forrest JI; Nachega JB; Senchaudhuri E; Mills EJ
Am J Trop Med Hyg; 2021 Jan; 104(1):35-38. PubMed ID: 33236703
[TBL] [Abstract][Full Text] [Related]
53. Weighing and communicating evidence.
Nat Biotechnol; 2020 Aug; 38(8):903. PubMed ID: 32733107
[No Abstract] [Full Text] [Related]
54. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
[No Abstract] [Full Text] [Related]
55. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
[No Abstract] [Full Text] [Related]
56. Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis: A Meta-analysis.
Bitterman A; Martins CP; Cices A; Nadendla MP
JAMA Netw Open; 2022 Mar; 5(3):e223079. PubMed ID: 35311963
[TBL] [Abstract][Full Text] [Related]
57. Publication and Impact of Preprints Included in the First 100 Editions of the CDC COVID-19 Science Update: Content Analysis.
Otridge J; Ogden CL; Bernstein KT; Knuth M; Fishman J; Brooks JT
JMIR Public Health Surveill; 2022 Jul; 8(7):e35276. PubMed ID: 35544426
[TBL] [Abstract][Full Text] [Related]
58. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.
Chan K; Sharif S; Rochwerg B
CJEM; 2021 Mar; 23(2):159-161. PubMed ID: 33534117
[No Abstract] [Full Text] [Related]
59. Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
Rathi S; Ish P; Kalantri A; Kalantri S
Lancet Infect Dis; 2020 Oct; 20(10):1118-1119. PubMed ID: 32311324
[No Abstract] [Full Text] [Related]
60. Living the SARS-CoV-2 pandemic in Turkey.
Çağdaş D
Nat Immunol; 2021 Mar; 22(3):260. PubMed ID: 33627882
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
